BioAtla, Inc. (BCAB) Social Stream



BioAtla, Inc. (BCAB): $3.52

0.58 (+19.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

BioAtla Inc (BCAB) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering BCAB.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-18 4 $75 $64 $70.5 $4.47 1477.18%
2022-01-02 4 $75 $58 $69 $4.47 1443.62%
2022-01-12 3 $75 $58 $69 $4.47 1443.62%
2022-01-17 3 $75 $58 $67.25 $4.47 1404.47%
2022-02-04 3 $68 $36 $57.5 $4.47 1186.35%
2022-03-01 3 $68 $36 $53.5 $4.47 1096.87%
2022-03-11 3 $68 $31 $46.75 $4.47 945.86%
2022-03-21 4 $68 $25 $42.4 $4.47 848.55%

The Trend in the Analyst Price Target


BCAB's average price target has moved down $33.85 over the prior 32 weeks.

BCAB reports an average of 240.68% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-02 4 87 68 76.67 40.64 88.66%
2021-08-28 4 87 68 76.25 40.86 86.61%
2021-11-16 4 75 64 70.50 27.82 153.41%
2022-03-01 3 68 36 53.50 6.45 729.46%
2022-03-11 4 68 31 46.75 5.18 802.51%

BCAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The Trend in the Broker Recommendations


Over the past 39 weeks, BCAB's average broker recommendation rating improved by 0.5.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • BCAB has a higher upside potential (average analyst target price relative to current price) than 893.28% of all US stocks.
  • BioAtla Inc's number of analysts covering the stock is greater than 103.6% of stocks in the mid market cap category.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, BioAtla Inc's variance in analysts' estimates is lower than -417.3% of them.
  • In terms of how BioAtla Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 653.95% of that group.

In the Pharmaceutical Products industry, ALVR, ALLO, and AERI are the three stocks most similar to BioAtla Inc regarding the price target and analyst recommendation information presented here.

Is BCAB a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3814 seconds.